Treatment of AL-amyloidosis with dexamethasone plus alpha interferon

Leukemia and Lymphoma

Volumn 27, Issue 3-4, 1997, Pages 351-356

  Dhodapkar, Madhav V ^a,b   Jagannath, Sundar ^a   Vesole, David ^a   Munshi, Nikhil ^a   Naucke, Sally ^a   Tricot, Guido ^a   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE   (United States)

Author keywords

AL amyloidosis; Alpha interferon; Amyloidosis; Dexamethasone; Treatment

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; DEXAMETHASONE;

AMYLOIDOSIS; ARTICLE; BIOPSY; CONGESTIVE HEART FAILURE; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY DISEASE; LEUKEMOGENESIS; LIVER DISEASE; MAINTENANCE THERAPY; PRIORITY JOURNAL; PROTEINURIA;

EID: 0030828170     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709059690     Document Type: Article

References (14)

1. Stone. M. J. (1990). Amyloidosis: a final common pathway for protein deposition in tissues. Blood, 75, 531-545.
2. Kyle, R. A. and Gertz, M. A. (1995). Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol, 32, 45-59.
3. Tan, S. Y., Pepys, M. B. and Hawkins, P. N. (1995). Treatment of amyloidosis. Am J Kidney Dis. 26, 267-285.
4. Gertz, M, A. and Kyle, R. A. (1990). Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Int Med, 150, 629-633.
5. Gianni, L., Bellotti, V., Gianni, A. and Merlini. G. (1995). New drug therapy of amyloidoses: resorption of AL type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood. 86, 855-861.
6. Alexanian, R., Dimopoulos, M., Delasalle, K. and Barlogie, B. (1992). Primary dexamethasone treatment of multiple myeloma. Blood, 80, 887-890.
7. Cooper, M. R. (1988). Interferons in the management of multiple myeloma.Seminars Oncology, 15, 21-25.
8. Tanaka, H., Tanabe, O., Iwato. K., Asaouku, H., Ishikawa. H., Nobuyoshi, M. et al. (1989). Sensitive inhibitory effect of interferon alpha on M protein secretion of human myeloma cell lines. Blood. 74, 1718-22.
9. Gertz, M. A., Kyle, R. A. and Greipp, P. R. (1991). Response rates and survival in primary systemic amyloidosis. Blood. 77. 257-262.
10. Kyle, R. A., Wagoner, R. D. and Holley, R. E. (1982). Primary systemic amyloidosis: resolution of nephrotic syndrome with melphalen and prednisone. Arch Int Med, 142, 1445-50.
11. Jagannath, S., Vesole, D., Glenn. L., Crowley, J. and Barlogic, B. (1992). Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support, Blood, 80, 1666-1672.
12. Skinner, M., Anderson, J. J., Simms, R., Falk, R., Wang, M., Libbey, C. A., Jones, L. A. and Cohen, A. S. (1996). Treatment of 100 patients with primary amyloidosis: a randomised trial of melphalan. prednisone and colchicine versus colchicine only. Am J Med, 100, 290-298.
13. Kyle, R. A., Greipp, P. R. and O'Fallon, W. M. (1986). Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases, Blood, 68, 220-224.
14. Gertz, M. A. and Kyle, R. A. (1993). Phase II trial of recombinant interferon alfa 2 in the treatment of primary systemic amyloidosis. Am J Hematol, 44, 125-128.